Laura Chow
Medical Oncology · Seattle, WANPI 1063745727
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $108,557 of the $114,298 with a category attached, or 95.0%. 23 manufacturers reported payments, led by Novartis at 26.1% of the total. Reporting peaked in 2020 at $42,446 and has fallen 99.4% since, to $253 in 2025. Among medical oncology clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 67 payments — averaging $1705.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$30K
- Sanofi$12K
- Merck$10K
- Daiichi Sankyo Inc.$10K
- AstraZeneca$9K
- Pfizer$8K
- plus $35K from 17 others
Across 45 payments — averaging $11,398 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$176K
- E.r. Squibb & Sons, L.L.C.$111K
- Pfizer$85K
- AstraZeneca$54K
- Roche Products Limited$48K
- Merck$28K
- plus $11K from 3 others
What the payments were for
- Consulting fees$108,55795%
- Speaking & faculty fees$2,4252%
- Travel & lodging$2,2852%
- Food & beverage$8681%
- Education$1620%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 5 | $29,855 |
| Sanofi | 5 | $12,062 |
| Merck | 18 | $10,486 |
| Daiichi Sankyo Inc. | 5 | $9,783 |
| AstraZeneca(2 entities) | 4 | $8,584 |
| Pfizer | 5 | $8,350 |
| Alkermes, Inc. | 3 | $7,600 |
| Ipsen Biopharmaceuticals, Inc | 1 | $6,200 |
| Dynavax Technologies Corporation | 3 | $5,538 |
| Regeneron Healthcare Solutions, Inc. | 1 | $3,275 |
| Gilead | 1 | $3,040 |
| F. Hoffmann-la Roche AG | 1 | $2,425 |
| EMD Serono, Inc. | 2 | $2,140 |
| Jazz Pharmaceuticals Inc. | 1 | $1,920 |
| Novartis Pharma AG | 1 | $1,875 |
| Regeneron | 1 | $544 |
| Seagen Inc. | 1 | $152 |
| E.r. Squibb & Sons, L.L.C. | 3 | $135 |
| Immunocore Limited | 1 | $125 |
| Lilly USA, LLC | 1 | $100 |
| Bristol Myers Squibb | 2 | $53 |
| AbbVie | 1 | $30 |
| Blueprint Medicines Corporation | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$114,298 in reported general payments places this provider in the 90th percentile of 162 medical oncology providers in Washington.
Other medical oncology in Seattle
- Bart ScottSeattle$1.3M
- Petros GrivasSeattle$628K
- Vijayakrishna GadiSeattle$573K
- Evan YuSeattle$296K
- Siddhartha DevarakondaSeattle$215K
- David MaloneySeattle$150K
- Gary LymanSeattle$130K
- Rafic FarahSeattle$114K
- Shailender BhatiaSeattle$107K
- Diane TsengSeattle$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.